PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24096584-6 2014 Importantly, mutation(s) of the type like deletion of A nucleotide and missense mutation (Gly > Val) exclusively showed low (+) or no expression for the CYP1A1 protein when studied in relation to each other. Valine 99-102 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 156-162 24629213-6 2014 RESULTS: We found an independent association of CYP1A1 (Val) and CYP17 (A1) with BC risk.Furthermore, an increased BC risk was observed for women with high serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) and carriers of at least: one CYP1A1 variant Val allele; one variant COMT Met allele; or the common CYP17 A1 allele. Valine 56-59 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 48-54 24629213-6 2014 RESULTS: We found an independent association of CYP1A1 (Val) and CYP17 (A1) with BC risk.Furthermore, an increased BC risk was observed for women with high serum levels of perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) and carriers of at least: one CYP1A1 variant Val allele; one variant COMT Met allele; or the common CYP17 A1 allele. Valine 56-59 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 269-275 24357096-9 2014 RESULTS: The results suggests a protective effect of the genotypes Arg/Lys of AhR rs2066853 (odds ratio [OR] 0.55, p = 0.03), Ile/Val of CYP1A1 rs1048943 (OR 0.49, p = 0.009), Tyr/His of EPHX1 rs1051740 (OR 0.53, p = 0.03), and A/A of CCND1 rs603965 (OR 0.44, p = 0.02). Valine 130-133 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 137-143 21710246-9 2012 With respect to CYP1A1 Ile ( 462 ) Val polymorphism, a total of 14 studies including 6,654 cases and 7,859 controls were involved in this meta-analysis. Valine 134-137 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 16-22 22948778-6 2012 Overall, CYP1A1 Ile462Val polymorphism was associated with increased risk of cervical cancer (Val versus Ile, OR = 1.43; 95 % CI, 1.03-1.97; ValVal versus IleIle, OR = 2.43; 95 % CI, 1.19-4.95; ValVal+ValIle versus IleIle, OR = 1.59; 95 % CI, 1.00-2.53). Valine 22-25 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 9-15 21710246-10 2012 The CYP1A1 Ile ( 462 ) Val polymorphism was associated with risk of colorectal cancer. Valine 122-125 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 4-10 22448487-2 2011 Especially pronounced changes of the above parameters were observed in men with mutant alleles Val of CYP1A1 gene. Valine 95-98 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 102-108 23056546-9 2012 The overall data indicated a significant association of CYP1A1 Ile462Val polymorphism with acute leukemia risk (Val/Val vs Ile/Ile OR = 1.49; 95% CI = 1.11-1.98; dominant model: OR = 1.26; 95% CI = 1.05-1.51; recessive model: OR = 1.38; 95% CI = 1.04-1.83). Valine 69-72 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 56-62 22395499-11 2012 The presence of Ile/Val polymorphism of CYP1A1 gene was identified in 9.5% of the cases and the MspI polymorphism of CYP1A1 gene was not identified in our subjects. Valine 20-23 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 40-46 14734460-6 2004 Cases with Ile/Val at CYP1A1 codon 462 were 2.6-fold and those with Val/Val were 5.1-fold more likely to have first-degree relatives with breast cancer than those with Ile/Ile (P = 0.002). Valine 15-18 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 22-28 19538838-6 2009 In oven-top group and oven-side group, the subjects with Val/Val genotype in exon 7 of CYP1A1 had significantly higher urinary 1-hydroxypyrene levels than those with Ile/Val or Ile/Ile genotype, and urinary 1-hydroxypyrene of Ile-Val genotype were also significantly higher than Ile/Ile genotype (P<0.01). Valine 57-60 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 87-93 19538838-6 2009 In oven-top group and oven-side group, the subjects with Val/Val genotype in exon 7 of CYP1A1 had significantly higher urinary 1-hydroxypyrene levels than those with Ile/Val or Ile/Ile genotype, and urinary 1-hydroxypyrene of Ile-Val genotype were also significantly higher than Ile/Ile genotype (P<0.01). Valine 61-64 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 87-93 19538838-6 2009 In oven-top group and oven-side group, the subjects with Val/Val genotype in exon 7 of CYP1A1 had significantly higher urinary 1-hydroxypyrene levels than those with Ile/Val or Ile/Ile genotype, and urinary 1-hydroxypyrene of Ile-Val genotype were also significantly higher than Ile/Ile genotype (P<0.01). Valine 61-64 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 87-93 18339256-6 2008 The rate of the CYP1A1 isoleucine (Ile)/valine (Val) allele was significantly higher in patients with PCOS than in the controls (OR: 7.8, 95% CI: 3.45-17.52, P < 0.001). Valine 40-46 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 16-22 18339256-6 2008 The rate of the CYP1A1 isoleucine (Ile)/valine (Val) allele was significantly higher in patients with PCOS than in the controls (OR: 7.8, 95% CI: 3.45-17.52, P < 0.001). Valine 48-51 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 16-22 17531965-3 2007 RESULTS: The age-adjusted odds ratios (ORs) for the Ile/Val genotype of CYP1A1 Ile462Val polymorphism in women and the Arg/Pro genotype of TP53 Arg72Pro polymorphism in men were observed to be 2.70 (95% CI: 1.14-6.40) and 4.32 (95% CI: 1.08-17.2), respectively. Valine 56-59 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 72-78 17531965-5 2007 CONCLUSION: These results suggest that the Val allele of CYP1A1 Ile462Val polymorphism and the Pro allele of TP53 Arg72Pro polymorphism contribute to an increased risk of GBC among Japanese women and men, respectively. Valine 43-46 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 57-63 18078203-4 2007 An unexpected 56.7% frequency of the CYP1A1*3 allele (which depends on the presence of a Val residue in the 462 position of the enzyme, instead of Ile) was found, the highest described for open populations of different ethnic origins (i.e., Caucasian, Asian, African, or African American). Valine 89-92 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 37-43 16235998-5 2005 Among the subjects, the genotype frequency of CYP1A1 Ile462Val was 56.8% for Ile/Ile, 38.1% for Ile/Val and 5.1% for Val/Val. Valine 59-62 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 46-52 16235998-5 2005 Among the subjects, the genotype frequency of CYP1A1 Ile462Val was 56.8% for Ile/Ile, 38.1% for Ile/Val and 5.1% for Val/Val. Valine 100-103 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 46-52 16235998-5 2005 Among the subjects, the genotype frequency of CYP1A1 Ile462Val was 56.8% for Ile/Ile, 38.1% for Ile/Val and 5.1% for Val/Val. Valine 100-103 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 46-52 15849806-10 2005 RESULTS: Individuals with the Ile-Val substitution in CYP1A1 exon 7 had increased esophageal cancer risk, with ORs (95%CI) compared with Ile/Ile of 1.37 (1.09-1.71), 2.52 (1.62-3.91) and 1.44 (1.17-1.78) for Ile-Val, Val/Val genotype and the combined group. Valine 34-37 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 54-60 11675150-7 2001 The estimated relative risk for lung cancer associated to a single mutated allele in CYP1A1, CYP2E1 or GSTM1 was 2.41 for m2, 1.69 for val, 1.16 for C, 0.71 for c2 and 2.46 for GSTM1(-). Valine 135-138 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 85-91 14510941-5 2003 However, when the MLH1 genotypes were combined with genotypes previously shown to influence ALL susceptibility, we found that the MLH1 variant Val-219 further increases the risk of GSTM1 null and CYP1A1*2A genotypes [combined odds ratio (OR) = 6.0, P = 0.002] as well as that of CYP2E1*5 (OR = 15.8, P = 0.001). Valine 143-146 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 196-202 11564581-9 2001 In the case of CYP1A1 m2 allele, 51% of oral cancers and 17% of normal controls, respectively, had one or both alleles with the isoleucine-->valine substitution. Valine 144-150 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 15-21 11564581-14 2001 The risk of CYP1A1 can be supported by the functional difference between presence of valine and isoleucine; valine type has higher catalytic and mutagenic activity towards benzo[a] pyrene than the isoleucine type. Valine 85-91 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 12-18 11564581-14 2001 The risk of CYP1A1 can be supported by the functional difference between presence of valine and isoleucine; valine type has higher catalytic and mutagenic activity towards benzo[a] pyrene than the isoleucine type. Valine 108-114 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 12-18 11468695-4 2001 Isoleucine (Ile)-valine (Val) and Val-Val genotypes of the CYP1A1 exon 7 polymorphism are associated with an increased risk for lung cancer in certain populations. Valine 34-37 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 59-65 11406420-6 2001 Our study suggested that the null GSTM1 genotype, independently or in combined with at least one Val allele of CYP1A1, might affect the genetic susceptibility for lung carcinoma in Chinese population. Valine 97-100 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 111-117 11468695-4 2001 Isoleucine (Ile)-valine (Val) and Val-Val genotypes of the CYP1A1 exon 7 polymorphism are associated with an increased risk for lung cancer in certain populations. Valine 34-37 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 59-65 11275366-2 2001 The frequency of valine (Val)/valine (Val) genotypes for CYP1A1 was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57). Valine 30-36 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 57-63 11275366-2 2001 The frequency of valine (Val)/valine (Val) genotypes for CYP1A1 was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57). Valine 17-23 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 57-63 11275366-2 2001 The frequency of valine (Val)/valine (Val) genotypes for CYP1A1 was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57). Valine 25-28 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 57-63 11275366-2 2001 The frequency of valine (Val)/valine (Val) genotypes for CYP1A1 was 11.3% in cases compared with 5.5% in controls, this polymorphism thus being associated with a significantly increased risk of PCa (odds ratio=2.4, 95% confidence interval (CI)=1.01-5.57). Valine 38-41 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 57-63 11860825-7 2000 The frequency of CYP1A1 genotype with at least one allele of Val (I/V and V/V) was also statistically higher in patients with GSTM1 (+), comparing to the corresponding controls (64% versus 41%, P < 0.05). Valine 61-64 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 17-23 11008920-2 2000 A point mutation at codon 462 in exon 7 of CYP1A1 results in a substitution of isoleucine by valine near the heme binding site. Valine 93-99 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 43-49 21528215-6 1997 The incidence of p53 gene mutation CYP1A1; Val/Val (60.0%), CYP1A1; C (50.0%) tended to be higher than those of CYPIAI; Ile/Ile and Ile/Val (40.4%) or CYP1A1; A and B (40.5%). Valine 43-46 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 35-41 10599336-6 1999 Two polymorphisms of the human CYP1A1 gene, a point mutation in the 3" flanking region of the gene (Msp1) and a mutation in exon 7 leading to an isoleucine-valine-exchange in the heme-binding region of the enzyme, have been described and may lead to a higher basal and inducible enzyme activity. Valine 156-162 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 31-37 10599336-14 1999 The observed increased frequencies of the CYP1A1 mutant Val-allele and the slow actylator phenotype in idiopathic autoimmune disease support our concept that in slow acetylators non-acetylated xenobiotics may accumulate and are subsequently metabolized by other enzymes into reactive intermediates. Valine 56-59 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 42-48 9718223-9 1998 There was a slightly higher percentage of DNA detectable adducts in subjects with CYPIA1 exon 7 valine polymorphism. Valine 96-102 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 82-88 9731721-10 1998 Interestingly, high frequencies for the rare m2 and Val alleles of the CYP1A1 gene were found in Mapuches (0.821 and 0.91, respectively), and the rare Val/m2 haplotype was significantly higher in Mapuches (0.748) than in Asians (0.24) (P < 0.01). Valine 52-55 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 71-77 9486585-7 1998 Presence of the rare valine in the CYP1A1/Nco1 site was found in 33 patients with HNSCC (17.8%), in 20 patients with BHNL (25.6%), and in 34 blood donors (16.4%). Valine 21-27 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 35-41 21528215-6 1997 The incidence of p53 gene mutation CYP1A1; Val/Val (60.0%), CYP1A1; C (50.0%) tended to be higher than those of CYPIAI; Ile/Ile and Ile/Val (40.4%) or CYP1A1; A and B (40.5%). Valine 47-50 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 35-41 9070254-1 1997 A genetic polymorphism (A4889-->G) in the human CYP1A1 gene which creates an Ile462-->Val amino acid substitution has been suggested to cause altered enzymatic properties of CYP1A1. Valine 92-95 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 51-57 9067549-5 1997 Smokers with the CYP1A1 exon 7 valine polymorphism had significantly higher (2-fold, P < or = 0.03) levels of DNA damage than those without. Valine 31-37 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 17-23 9070254-1 1997 A genetic polymorphism (A4889-->G) in the human CYP1A1 gene which creates an Ile462-->Val amino acid substitution has been suggested to cause altered enzymatic properties of CYP1A1. Valine 92-95 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 180-186 8752159-1 1996 Human cytochrome P4501A1 (CYP1A1) occurs extrahepatically and is polymorphic, the common form having Ile at position 462 and the rare form having Val. Valine 146-149 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 6-24 8752159-1 1996 Human cytochrome P4501A1 (CYP1A1) occurs extrahepatically and is polymorphic, the common form having Ile at position 462 and the rare form having Val. Valine 146-149 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 26-32 7627950-2 1995 A CYP1A1 polymorphism (isoleucine to valine substitution in exon 7) or the null allele for GSTM1 may affect the mutagenic potential of polycyclic aromatic hydrocarbons. Valine 37-43 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 2-8 7546226-6 1995 Adduct levels were also lower in the nine subjects heterozygous or homozygous for the CYP1A1 exon 7 polymorphism (which codes for a valine rather than isoleucine and is thought to be associated with greater CYP1A1 activity) compared with the 38 wild-type subjects (P = 0.12). Valine 132-138 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 86-92 7586131-9 1995 Combined CYP1A1 and GSTM1 genotype is thus a potential predictor of genetic susceptibility to smoking-related lung cancers in populations where CYP1A1 m2 or Val alleles are common. Valine 157-160 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 9-15 7581485-2 1995 Of the three polymorphisms studied, only the exon 7 polymorphism of CYP1A1 (Val-containing genotypes) had a distribution which was statistically significant in the patients and controls. Valine 76-79 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 68-74 7534543-2 1995 The Val-containing genotype in exon 7 of CypIA1 was found to be associated with lung cancer in this population (odds ratio, 2.26; 95% confidence interval, 1.14-4.47 for 99 cases versus 108 controls of 123 matched pairs), whereas RsaI polymorphism in CypIIE1 was not associated with lung cancer susceptibility. Valine 4-7 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 41-47 7581485-3 1995 The contribution of Val containing genotypes of CYP1A1 exon 7 was greater in the subpopulation of squamous cell carcinoma patients with a lower life-time smoking consumption (OR, 2.92 vs 1.97). Valine 20-23 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 48-54 7516235-3 1994 This latter nucleotide change results in an altered amino acid (462Ile-->Val), which is purported to increase CYP1A1 enzyme activity and mutagenicity towards benzo[a]pyrene about two-fold among Japanese. Valine 76-79 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 113-119 8103989-2 1993 A Val/Ile codon difference in the primary structure of the CYP1A1 protein (Val-, Ile-type) was in linkage disequilibrium with the Msp I RFLP. Valine 2-5 cytochrome P450 family 1 subfamily A member 1 Homo sapiens 59-65